trending Market Intelligence /marketintelligence/en/news-insights/trending/ykslyga4ptqcltlnxsv20w2 content esgSubNav
In This List

Eisai books 31.7% YOY rise in FY'18 profit

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Eisai books 31.7% YOY rise in FY'18 profit

Eisai Co. Ltd. said profit for the year ended March 31 rose 31.7% year over year, while revenue grew 11.3%.

Profit attributable to owners was about ¥51.85 billion for the fiscal year, up from about ¥39.36 billion a year ago.

The Tokyo-based pharmaceutical company's diluted EPS was ¥180.97, up from ¥137.41 for the fiscal year ended March 31, 2017.

Revenue for fiscal year 2018 reached about ¥600.05 billion, up from about ¥539.1 billion a year earlier.

Eisai attributed the rise in revenue to the growth in sales of anticancer drugs Halaven and Lenvima and rheumatoid arthritis drug Humira, among others. Total revenue from the Japan segment reached ¥296.17 billion, up 1.8% year over year, while sales in the Americas stumbled, dropping 2.2% to ¥113.92 billion.

Payments under the company's partnership with Merck & Co. Inc. also boosted Eisai's overall revenue.

The Japanese pharma's operating profit totaled ¥77.21 billion, up 30.7% year over year, as the increase in revenue outweighed the aggressive research and development investment in Alzheimer's disease and oncology projects.

For the fiscal year ending March 31, 2019, the company expects profit attributable to owners to rise 10.9% to ¥57.5 billion. Revenue is expected to grow 5.3% to ¥632 billion.

As of May 14, US$1 was equivalent to ¥109.61.